Allergen-specific immunotherapy with monomeric allergoid from house dust mites dermato-phagoides pteronyssinus in a mouse allergic rhinitis model
- Authors: Laskin AA1, Babakhin AA1, Kamishnikov OY1, Gushchin IS1, Khaitov MR1
-
Affiliations:
- Institute of Immunology
- Issue: Vol 13, No 6 (2016)
- Pages: 43-51
- Section: Articles
- URL: https://journals.rcsi.science/raj/article/view/120615
- DOI: https://doi.org/10.36691/RJA367
- ID: 120615
Cite item
Full Text
Abstract
Full Text
##article.viewOnOriginalSite##About the authors
A A Laskin
Institute of ImmunologyMoscow, Russia
A A Babakhin
Institute of Immunology
Email: alexbabahin@list.ru
Moscow, Russia
O Y Kamishnikov
Institute of ImmunologyMoscow, Russia
I S Gushchin
Institute of ImmunologyMoscow, Russia
M R Khaitov
Institute of ImmunologyMoscow, Russia
References
- Akdis M. New treatments for allergen immunotherapy. World Allergy Organization Journal. 2014, v. 7, p. 23-27.
- Howarth P., Malling H.J., Molimard M., Devillier P Analysis of allergen immunotherapy studies shows increased clinical efficacy in highly symptomatic patients. Allergy. 2012, v. 67, p. 321-327.
- Курбачева О.М., Ильина Н.И. Лечение аллергического ринита: когда, как и зачем? Рос. Аллергол. Журн. 2006, № 2, с. 66-75.
- Noon L. Prophylactic inoculation against hay fever. Lancet. 1911, v. 1, p. 1572-1573.
- Freeman J. Further observation of the treatment of hay fever by hypodermic inoculations of pollen vaccines. Lancet. 1911, v. 2, p. 814-817.
- Nelson H.S. Allergen Immunotherapy. Where is it now? J. Allergy Clin. Immunol. 2007, v. 119, p. 769-777.
- Epstein TG., Liss G.L., Murphy-Berendts K., Bemstein D.I. Risk factors for fatal and nonfatal reactions to subcutaneous immunotherapy: National surveillance study on allergen immunotherapy (2008-2013). Ann. Allergy, Asthma, Immunol. 2016, v. 116, p. 354-359.
- Бабахин А.А., Гущин И.С., Андреев С.М. и соавт. Химическая модификация аллергена, ведущая к изменению его эпитопной активности. Пат. физиол. 1999, № 1, с. 17-20.
- Platt-Mills T.A. The future of allergy and clinical immunology lies in evaluation, treatment and research on allergic disease. J. Allergy Clin. Immunol. 2002, v. 110, p. 565-566.
- Platt-Mills T.A., Ervin E.A., Heymann P.W., Woodfolk J.I. Pro: The evidence for a causal role of dust mites in asthma. Am. J. Respir. Crit. Care Med. 2009, v. 180, p. 109-121.
- Cui Y. Structural biology of mite allergens. Mol. Biol. Resp. 2013, v. 40, p. 681-686.
- Бабахин А.А., Ласкин А.А., Смирнов В.В. и соавт. Мономерный аллергоид из клещей домашней пыли Dermatophagoides pteronyssinus: иммунологические свойства. Рос. Аллергол. Журн. 2016, № 4-5, с. 29-36.
- Бабахин А.А., Ласкин А.А., Камышников О.Ю. и соавт. Модель экспериментальной бронхиальной астмы, индуцированной у мышей аллергенным экстрактом из клещей домашней пыли Dermatophagoides pteronyssinus. Рос. Аллергол. Журн. 2015, № 6, с. 25-33.
- Лилли Р.Д. Руководство «Патогистологическая техника и практическая гистохимия» (пер. с англ.). М., 1969, 646 с.
- Ennis D.P., Cassidy J.P., Mahon B.Pю Acellular Pertussis Vaccine Protects against Exacerbation of Allergic Asthma Due to Bordetella pertussis in a Murine Model. Clin. Diagnostic. Lab. Immun. 2005, v. 3, p. 409-417.
- Van Oosternhout A.J., van Esch B., Hofman G., Hofstra C.L., van Ark I., Nijkamp F.P., Weller F.R. Allergen immunotherapy inhibits airway eosinophilia and hyperresponsiveness associated with decreased IL-4 production by lymphocytes in a mature model of allergic asthma. Am. J. Respir. Cell. Mol. Biol. 1998, v. 4, p. 622-628.
- Jenssen E.M., van Oosterhout A.J., van Rensen A.J. et al. Modulation of Th2 responses by peptide analogues in a murine model of allergic asthma: amelioration ordeterioration of the disease process depends on Th1 or Th2 skewing characteristics of the therapeutic peptide. J. Immunol. 2000, v. 164, p. 580-588.
- Durham S.R., Nelson H. Allergen immunotherapy: A Centenary celebration. WAO Journal. 2011, v. 4, p. 104-106.
- Takahashi Y., Kagawa Y., Izawa K. et al. Effect of histamine H4 receptor antagonist on allergic rhinitis in mice. Int. Immunopharmacol. 2009, v. 9, p. 734-738.
- Wagner J.G., Harkema J.R. Rodent models of allergic rhinitis: Relevance to human pathophysiology. Curr. Allergy Asthma Rep. 2007, v. 7, p. 134-140.
- Shin J.H., Kim B.Y., Park H.R., Kim S.W. The effect of pneumococcal polysaccharide vaccine in a mouse model of allergic rhinitis. Otolaryngol. Head Neck Surg. 2013, v. 148, p. 383-390.
- Tasaniyananda N., Chaisri U., Tungtrongchitr A. et al. Mouse model of cat allergic rhinitis and intranasal liposome-adjuvanted refined Fel d 1 vaccine. PLoS One. 2016, v. 11, e0150463c.
- Huang C.F., Wu T.C., Chu Y.H. et al. Effect of neonatal sublingual vaccination with native or denatured ovalbumin and adjuvant CpG or cholera toxin on systemic and mucosal immunity in mice. Scand. J. Immunol. 2008, v. 68, p. 502-510.
- Rask C., Brimnes J., Lund K. Shorter dosing intervals of sublingual immunotherapy lead to more efficacious treatment in a mouse model of allergic inflammation. Scand J. Immunol. 2010, v. 71, p. 403-412.
- Nacaroglu H.T., Erdem S.B., Sumer O. et al. Local and systemic reactions to subcutaneous allergen immunotherapy: Ten years’ experience in a pediatric clinic. Ann. Allergy Asthma Immunol. 2016, v. 116, p. 349-353.
- Epstein T.G., Liss G.L., Murphy-Berendts K., Bemstein D.I. Risk factors for fatal and nonfatal reactions to subcutaneous immunotherapy: National surveillance study on allergen immunotherapy (2008-2013). Ann. Allergy Asthma Immunol. 2016, v. 116, p. 354-359.